Edwards Lifesciences (NYSE:EW) traded lower in the premarket on Thursday after Wolfe Research downgraded the heart device ...

Geneos Wealth Management Inc. decreased its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.3% ...

Brighton Jones LLC purchased a new position in Edwards Lifesciences Co. (NYSE:EW – Free Report) in the fourth quarter, ...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”) ...

Wolfe Research downgraded Edwards Lifesciences (EW) to Underperform from Peer Perform with a $60 price target The firm says its core ...

Today, Benzinga's options scanner spotted 8 options trades for Edwards Lifesciences. This is not a typical pattern. The ...

Edwards Lifesciences Corp. engages in the patient ... Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter ...

$390,000 of EDWARDS LIFESCIENCES LLC lobbying was just disclosed ... guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees ...

Edwards Lifesciences Corp (EW) stock saw a modest uptick, ending the day at $68.99 which represents a slight increase of $0.06 or 0.09% from the prior close of $68.93. The stock opened at $68.64 and ...

Citi analyst Joanne Wuensch maintained a Buy rating on Edwards Lifesciences (EW – Research Report) today. The company’s shares closed yesterday ...